Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamar H Taddei

Showing results (31-40 of 136) with videos related to

Pageof 14
Sort By:
JAMA Network Open|July 22, 2025
Adaptation of Risk Score for Hepatocellular Carcinoma Without Alcohol MeasuresJanet P Tate, Tamar H Taddei, Vincent Lo Re, et al.
Transplantation|July 9, 2019
Survival Benefit of Liver Transplantation for Hepatocellular CarcinomaMounika Kanneganti, Nadim Mahmud, David E Kaplan, et al.
Hepatology (Baltimore, Md.)|November 3, 2019
Grade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 FailureNadim Mahmud, Vinay Sundaram, David E Kaplan, et al.
Journal of Vascular and Interventional Radiology : JVIR|February 26, 2018
Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity MatchingDavid E Kaplan, Rajni Mehta, Kathryn D'Addeo, et al.
The American Journal of Gastroenterology|September 17, 2022
Patterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the PandemicMarina Serper, Elliot B Tapper, David E Kaplan, et al.
The American Journal of Gastroenterology|July 25, 2024
The Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related OutcomesRoy X Wang, Marina Serper, Tamar H Taddei, et al.
Hepatology (Baltimore, Md.)|May 4, 2021
REPLYBinu V John, Bassam Dahman, Tamar H Taddei, et al.
Gastroenterology|January 12, 2021
Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 PandemicNadim Mahmud, David E Kaplan, David S Goldberg, et al.
Hepatology (Baltimore, Md.)|August 22, 2022
Attacking the public health crisis of hepatocellular carcinoma at its rootsHannah M Lee, Steven D Lidofsky, Tamar H Taddei, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVESAdeel A Butt, Yanjie Ren, Vincent Lo Re, et al.
Pageof 14

Showing results (31-40 of 136) with videos related to

Sort By:
Pageof 14
JAMA Network Open|July 22, 2025
Adaptation of Risk Score for Hepatocellular Carcinoma Without Alcohol MeasuresJanet P Tate, Tamar H Taddei, Vincent Lo Re, et al.
Transplantation|July 9, 2019
Survival Benefit of Liver Transplantation for Hepatocellular CarcinomaMounika Kanneganti, Nadim Mahmud, David E Kaplan, et al.
Hepatology (Baltimore, Md.)|November 3, 2019
Grade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 FailureNadim Mahmud, Vinay Sundaram, David E Kaplan, et al.
Journal of Vascular and Interventional Radiology : JVIR|February 26, 2018
Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity MatchingDavid E Kaplan, Rajni Mehta, Kathryn D'Addeo, et al.
The American Journal of Gastroenterology|September 17, 2022
Patterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the PandemicMarina Serper, Elliot B Tapper, David E Kaplan, et al.
The American Journal of Gastroenterology|July 25, 2024
The Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related OutcomesRoy X Wang, Marina Serper, Tamar H Taddei, et al.
Hepatology (Baltimore, Md.)|May 4, 2021
REPLYBinu V John, Bassam Dahman, Tamar H Taddei, et al.
Gastroenterology|January 12, 2021
Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 PandemicNadim Mahmud, David E Kaplan, David S Goldberg, et al.
Hepatology (Baltimore, Md.)|August 22, 2022
Attacking the public health crisis of hepatocellular carcinoma at its rootsHannah M Lee, Steven D Lidofsky, Tamar H Taddei, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVESAdeel A Butt, Yanjie Ren, Vincent Lo Re, et al.
Pageof 14